Ovid Therapeutics Inc. Common Stock (OVID)

FairStock Score: 57/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Ovid Therapeutics is a clinical-stage biopharmaceutical company with 23 employees, developing small-molecule medicines for epilepsies and seizure-related neurological disorders. Its candidates OV329 and OV4071 remain in Phase 1 trials, so the business has no approved product and no durable commercial moat I can identify today. Revenue is tiny and erratic: fiscal 2025, ended 2025-12-31, produced $7.3M of revenue, yet fiscal Q2 2026, ended 2026-06-30, had only $733,000, down sharply from $6.3M in fiscal Q2 2025, ended 2025-06-30. FairStock's revenue growth of -88.31% reflects that swing. Losses remain substantial: fiscal 2023 net loss was $52.3M, fiscal 2024 net loss $26.4M, fiscal 2025 net loss $17.4M, and in fiscal Q1 2026, ended 2026-03-31, net loss was $17.0M, followed by a $15.0M net loss in fiscal Q2 2026. Free cash flow is negative $54.8M over the trailing twelve months, a -12.8% FCF yield on the $427.7M market cap. The balance sheet shows low leverage-D/E 0.06-and FairStock's Altman Z-Score is 9.85, but Piotroski is 2/9, so accounting quality is weak. At the 2026-10-13 close of $2.19, P/B is 1.92; P/E is -10.43 and meaningless without earnings. FairStock's score is 57/100, and the computed Lynch category is none because the company has lost money in each of the last four years. This is not a Graham bargain grounded in earnings or assets; it is a speculative option on clinical trial success. I would demand evidence of trial progress and a credible path to profitability before assigning intrinsic value.

In plain English: Ovid Therapeutics is a small healthcare company trying to develop new medicines for brain disorders such as epilepsy. It has no approved products and is losing money, with very little and uneven revenue. At $2.19 a share, the price looks expensive compared with the current business numbers, because there are no profits yet and sales are tiny.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer